Our People

Dr. Rosen has been leading successful drug discovery and development organizations in the biotechnology and pharmaceutical industries for more than 30 years. In 2015, he co-founded Arcus, a drug discovery company focused on the treatment of cancer by blocking tumor-induced immunosuppression…. Previously, Dr. Rosen was co-founder and CEO of Flexus Biosciences, focusing on small molecule drugs that reverse tumor immunosuppression. He has held several executive positions at Amgen and Tularik, as well as scientific and management positions at Pfizer and Abbott Laboratories. Dr. Rosen also serves on the boards of scientific institutions such as the Salk Institute Board of Trustees and the California Life Sciences Association.

Dr. Jaen has been engaged in all aspects of drug discovery and development for more than 30 years, and in 2015 he co-founded Arcus. Before starting Arcus, Dr. Jaen was co-founder and President of Flexus Biosciences. He was Chief Scientific Officer and SVP of Drug Discovery at ChemoCentryx for 7 years…, where he led the discovery and progression into the clinic of 8 novel immunology drug candidates. Dr. Jaen has also held various positions at Amgen, Tularik, and Parke-Davis/Warner-Lambert. He is an inventor on 50 patents and has helped the advancement of over 20 novel molecules into clinical development across a range of indications.

Ms. Jarrett is an accomplished executive in the healthcare and technology industries.  She most recently served as Vice President of Corporate Development and Capital Markets of Uber Technologies, Inc., and prior to this, was Chief Operating Officer and Chief Financial Officer of Arcus Biosciences. Ms. Jarrett has been an ongoing member… of Arcus’s board of directors since January 2019.  Prior to Arcus, Ms. Jarrett was Chief Financial Officer of Medivation, a commercial oncology company that developed XTANDI® (enzalutamide),  which has become an established standard-of-care therapy for the treatment of prostate cancer. Ms. Jarrett spent 20 years in investment banking, including an extensive tenure at Citigroup, where she ran the firm’s west coast life sciences investment banking practice, and prior to that at Credit Suisse and Donaldson, Lufkin & Jenrette. Ms. Jarrett also serves on the boards of Sagimet Biosciences, Syndax Pharmaceuticals and Zura Bio.

Mr. Goeltz has an extensive track record and breadth of experience in finance and accounting, most recently serving as Chief Financial Officer and Senior Vice President of UNITY Biotechnology and immediately before that as Chief Financial Officer of… CytomX Therapeutics, leading both of the companies’ IPOs and finance organizations. Prior to these positions, Mr. Goeltz had an 11-year tenure at Amgen, holding positions including the Chief Financial Officer of Onyx Pharmaceuticals after its acquisition by Amgen, and senior financial roles in commercial and R&D finance, business development and accounting. In his roles at Amgen, he was involved in multiple oncology product launches. Earlier in his career, he served as Director of Finance for Tularik. Mr. Goeltz began his career in the audit practice of EY. Mr. Goeltz received his Master of Business Administration degree from UCLA’s Anderson School of Management and his Bachelor of Business Administration degree from Emory University’s Goizueta School of Business.

Dr. Markus brings over 20 years of experience in biopharmaceuticals and clinical development to his role as chief medical officer at Arcus. Dr. Markus established a unique track record of late-stage development experience during a 13-year tenure at Amgen in increasing roles of responsibility, including as vice president of global development. … Dr. Markus oversaw the development and approval of multiple products and was also the first R&D head for the biosimilars division, leading the development of a 10-product pipeline across multiple therapeutic areas, including oncology and rheumatology. He also oversaw the development that led to the approval of CAYSTON® for cystic fibrosis at Corus Pharma prior to its acquisition by Gilead. Most recently, Dr. Markus founded Dantari, a clinical-stage oncology-focused antibody-drug conjugate company, where he served as president, CEO and member of the Board. Dr. Markus received his M.D. and a Ph.D. in epidemiology from the University of Southern California.

After several years as a member of the Arcus Scientific Advisory Board, in 2020 Dr. Yingling joined Arcus as Senior Vice President, Research. As a member of the Research Leadership team, Dr. Yingling provides guidance to all aspects of our research, discovery and translational efforts, creating a key research interface with our Development organization. …

Throughout Dr. Yingling’s long tenure in the pharmaceutical/biotech industry, he has held senior leadership positions in the R&D organizations of several pillars of our sector, including BMS (VP, Oncology Discovery & Translational Research), and Lilly (VP Oncology Research and then VP Translational Science & Technology), as well as innovative biotech companies Idera Pharmaceuticals (CSO) and Bind Therapeutics (CSO). He has applied his extensive scientific expertise in oncology and translational research to the discovery and development of multiple cancer drugs. He also established and led global research and translational science partnerships in the U.S., Singapore, China and Europe. In addition, he championed and led major merger and acquisition transactions. Dr. Yingling has been involved in the discovery and development of more than 15 drug candidates, including galunisertib and merestinib.

Dr. Yingling earned his PhD in Cell and Molecular Biology and Pharmacology at Duke University and was a Howard Hughes Postdoctoral Fellow at Vanderbilt University. He has co-authored 65 scientific papers and is listed as inventor in 2 issued U.S. patents.

Ms. Tang is an attorney with broad expertise in transactions, intellectual property, securities, and corporate governance in the U.S. and Europe. Prior to joining Arcus, she worked at Medivation as well as InterMune, where she oversaw InterMune’s global IP portfolio and supported… the approval and commercialization of Esbriet®. Ms. Tang also helped establish and administer InterMune’s European subsidiaries and assisted in public offerings and common stock before the company’s acquisition by Roche.

Ms. Gehring is a seasoned Human Resources professional with more than 30 years of experience in the biopharmaceutical industry, specializing in talent management, organizational development, and compensation and benefits. … She joined Arcus in 2015 and currently serves as SVP, of human resources and operations. Prior to Arcus, she was head of human resources at ChemoCentryx, Inc. Previously, Ms. Gehring held roles with increasing responsibility in human resources at Theravance, Inhale, Systemix, and Genentech.